Analysts forecast that Teligent Inc (NASDAQ:TLGT) will post sales of $19.80 million for the current quarter, Zacks reports. Two analysts have provided estimates for Teligent’s earnings, with the highest sales estimate coming in at $20.50 million and the lowest estimate coming in at $19.10 million. Teligent reported sales of $13.66 million in the same quarter last year, which would suggest a positive year over year growth rate of 44.9%. The firm is expected to report its next quarterly earnings report on Monday, November 5th.
According to Zacks, analysts expect that Teligent will report full year sales of $72.27 million for the current year, with estimates ranging from $72.03 million to $72.50 million. For the next financial year, analysts forecast that the firm will post sales of $98.70 million, with estimates ranging from $90.90 million to $106.50 million. Zacks Investment Research’s sales calculations are an average based on a survey of analysts that follow Teligent.
Teligent (NASDAQ:TLGT) last announced its quarterly earnings data on Wednesday, August 8th. The company reported ($0.20) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.02) by ($0.18). The business had revenue of $16.75 million during the quarter, compared to the consensus estimate of $16.06 million. Teligent had a negative net margin of 62.19% and a negative return on equity of 50.85%.
Several equities analysts have commented on the company. Canaccord Genuity set a $4.00 price objective on Teligent and gave the company a “hold” rating in a research report on Tuesday, July 31st. Zacks Investment Research raised Teligent from a “sell” rating to a “hold” rating in a research report on Saturday, June 16th. Finally, ValuEngine downgraded Teligent from a “buy” rating to a “hold” rating in a research report on Tuesday, October 2nd.
In other Teligent news, CEO Jason Grenfell-Gardner sold 52,800 shares of the company’s stock in a transaction on Tuesday, September 4th. The stock was sold at an average price of $4.00, for a total value of $211,200.00. Following the completion of the sale, the chief executive officer now directly owns 94,949 shares in the company, valued at approximately $379,796. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 22.80% of the stock is currently owned by corporate insiders.
Hedge funds have recently modified their holdings of the business. JPMorgan Chase & Co. lifted its holdings in shares of Teligent by 225.7% in the 1st quarter. JPMorgan Chase & Co. now owns 33,731 shares of the company’s stock worth $274,000 after buying an additional 23,376 shares during the period. Raymond James Financial Services Advisors Inc. lifted its holdings in shares of Teligent by 83.9% in the 2nd quarter. Raymond James Financial Services Advisors Inc. now owns 94,443 shares of the company’s stock worth $327,000 after buying an additional 43,091 shares during the period. Citadel Advisors LLC lifted its holdings in shares of Teligent by 86.2% in the 1st quarter. Citadel Advisors LLC now owns 114,784 shares of the company’s stock worth $385,000 after buying an additional 53,141 shares during the period. A.R.T. Advisors LLC lifted its holdings in shares of Teligent by 255.9% in the 1st quarter. A.R.T. Advisors LLC now owns 170,414 shares of the company’s stock worth $572,000 after buying an additional 122,525 shares during the period. Finally, Guggenheim Capital LLC lifted its holdings in shares of Teligent by 8.7% in the 1st quarter. Guggenheim Capital LLC now owns 383,466 shares of the company’s stock worth $1,288,000 after buying an additional 30,532 shares during the period. Institutional investors and hedge funds own 68.72% of the company’s stock.
Teligent stock traded down $0.01 during mid-day trading on Monday, hitting $3.25. The company’s stock had a trading volume of 290,878 shares, compared to its average volume of 560,945. The company has a market capitalization of $211.48 million, a PE ratio of -17.11 and a beta of 1.13. The company has a quick ratio of 1.79, a current ratio of 2.77 and a debt-to-equity ratio of 3.31. Teligent has a one year low of $2.43 and a one year high of $7.08.
Teligent Company Profile
Teligent, Inc, a specialty generic pharmaceutical company, develops, manufactures, and markets generic topical, branded generic, and generic injectable pharmaceutical products in the United States and Canada. The company sells generic pharmaceutical products in topical, injectable, complex, and ophthalmic dosage forms.
Featured Story: How much money do you need to begin day trading?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Teligent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teligent and related companies with MarketBeat.com's FREE daily email newsletter.